These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31536751)

  • 1. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
    Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
    Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
    Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
    Gomes S; Bosco B; Loureiro JB; Ramos H; Raimundo L; Soares J; Nazareth N; Barcherini V; Domingues L; Oliveira C; Bisio A; Piazza S; Bauer MR; Brás JP; Almeida MI; Gomes C; Reis F; Fersht AR; Inga A; Santos MMM; Saraiva L
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.
    Ramos H; Calheiros J; Almeida J; Barcherini V; Santos S; Carvalho ATP; Santos MMM; Saraiva L
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis.
    Loureiro JB; Ribeiro R; Nazareth N; Ferreira T; Lopes EA; Gama A; Machuqueiro M; Alves MG; Marabini L; Oliveira PA; Santos MMM; Saraiva L
    Pharmacol Res; 2022 Jan; 175():106026. PubMed ID: 34890775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
    Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
    Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.
    Aggarwal M; Saxena R; Sinclair E; Fu Y; Jacobs A; Dyba M; Wang X; Cruz I; Berry D; Kallakury B; Mueller SC; Agostino SD; Blandino G; Avantaggiati ML; Chung FL
    Cell Death Differ; 2016 Oct; 23(10):1615-27. PubMed ID: 27258787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
    Ramos H; Soares MIL; Silva J; Raimundo L; Calheiros J; Gomes C; Reis F; Monteiro FA; Nunes C; Reis S; Bosco B; Piazza S; Domingues L; Chlapek P; Vlcek P; Fabian P; Rajado AT; Carvalho ATP; Veselska R; Inga A; Pinho E Melo TMVD; Saraiva L
    Cell Rep; 2021 Apr; 35(2):108982. PubMed ID: 33852837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.
    Loureiro JB; Raimundo L; Calheiros J; Carvalho C; Barcherini V; Lima NR; Gomes C; Almeida MI; Alves MG; Costa JL; Santos MMM; Saraiva L
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gambogic acid counteracts mutant p53 stability by inducing autophagy.
    Foggetti G; Ottaggio L; Russo D; Monti P; Degan P; Fronza G; Menichini P
    Biochim Biophys Acta Mol Cell Res; 2017 Feb; 1864(2):382-392. PubMed ID: 27899303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
    Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
    Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
    Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
    Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
    J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.